BlackRock Joins Goldfinch Bio's $100M Series B Round
Kidney disease-focused biotechnology company Goldfinch Bio Inc. has raised $100 million in a financing round led by Eventide Asset Management and attracting new investors including funds managed by BlackRock Investment LLC,...To view the full article, register now.
Already a subscriber? Click here to view full article